Detroit-based Barbara Ann Karmanos Cancer Institute has become the first independent cancer center in the U.S. to provide a one-time gene therapy for the treatment of hemophilia B in adults.
The first patient received the therapy — called Hemgenix — Oct. 28, according to a March 23 news release from the cancer institute.
The standard treatment for hemophilia B requires routine infusions of factor IX replacement therapy to help reduce bleeding risk. After gene therapy, patients need infusions only when undergoing a medical procedure or experiencing physical trauma.
